Thalidomide

FDA approval of teclistamab for R/R multiple myeloma and the value of immunotherapies

The treatment of young and fit, older and fit, and frail patients with multiple myeloma in Ireland

The current frontline treatment strategy in multiple myeloma

Current status of induction therapy for multiple myeloma

Early myelofibrosis: current treatment approaches and novel strategies

AGMT MM 02: KTd vs KRd induction therapy & carfilzomib maintenance in NDMM

The safety and efficacy of iberdomide for the treatment of multiple myeloma

Safety and efficacy of daratumumab, carfilzomib, pomalidomide & elotuzumab in POEMS syndrome

The safety and efficacy of belantamab mafodotin in R/R multiple myeloma in the real world

The impact of daratumumab on the myeloma treatment landscape

Promising novel agents for relapsed/refractory multiple myeloma

The importance of autologous transplantation in the era of immunotherapy

Recent updates on CELMoDs in multiple myeloma

The importance of induction therapy prior to autoSCT

The value of treating patients who are MRD negative

Treatment options for transplant-ineligble myeloma patients: the promise of combination therapies